BRNS
Barinthus Biotherapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$0.76
+5.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 15.0M | 802.0K | 44.7M |
| Cost of Revenue | 1.8M | 5.9M | — | — | — |
| Gross Profit | (1.8M) | (5.9M) | 15.0M | 802.0K | 44.7M |
| Operating Expenses | |||||
| R&D Expense | 16.6M | 25.6M | 38.3M | 41.4M | 41.1M |
| SG&A Expense | 19.4M | 40.8M | 29.7M | 39.8M | 6.4M |
| General & Admin Expense | 19.4M | 40.8M | 29.7M | 39.8M | 6.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 6.9M | (18.1M) | 15.0M | 3.5M | 1.2M |
| Total Operating Expenses | 42.8M | 48.3M | 82.9M | 84.7M | 48.7M |
| Cost and Expenses | 44.6M | 54.2M | 82.9M | 84.7M | 48.7M |
| Operating Income (EBIT) | (44.6M) | (54.2M) | (68.0M) | (83.9M) | (4.0M) |
| Non-Operating | |||||
| Interest Income | 1.6M | 2.0M | 2.7M | 2.9M | 3.1M |
| Interest Expense | 53.0K | 51.1K | 53.0K | 28.0K | 19.0K |
| Net Interest Income | 1.5M | 1.9M | 2.6M | 2.8M | 3.1M |
| Other Non-Op Income/Expense | 2.4M | (14.6M) | 6.7M | 7.4M | 4.9M |
| Non-Operating Income (excl Interest) | (2.4M) | 14.5M | (6.8M) | (7.4M) | (4.9M) |
| EBT (Pre-Tax Income) | (42.2M) | (68.8M) | (61.2M) | (76.5M) | 850.0K |
| Income Tax Expense | (431.5K) | (2.2M) | (44.0K) | (3.1M) | (4.5M) |
| Bottom Line | |||||
| Net Income | (41.7M) | (66.6M) | (61.1M) | (73.3M) | 5.3M |
| Earnings from Cont. Ops | (41.8M) | (66.6M) | (61.2M) | (73.4M) | 5.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (41.7M) | (66.6M) | (61.1M) | (73.3M) | 5.3M |
| Per Share | |||||
| Basic EPS | ($1.03) | ($1.64) | ($1.55) | ($1.91) | $0.14 |
| Diluted EPS | ($1.03) | ($1.64) | ($1.55) | ($1.91) | $0.14 |
| Revenue Per Share | $0.00 | $0.00 | $0.38 | $0.02 | $1.20 |
| Shares | |||||
| Basic Shares Outstanding | 40.8M | 40.5M | 39.3M | 38.4M | 37.2M |
| Diluted Shares Outstanding | 40.8M | 40.5M | 39.3M | 38.4M | 38.2M |
| Profitability Metrics | |||||
| EBITDA | (37.5M) | (62.9M) | (55.4M) | (71.1M) | 5.2M |
| D&A | 4.6M | 5.8M | 5.8M | 5.4M | 4.3M |
| EBIT | (42.2M) | (68.7M) | (61.2M) | (76.5M) | 869.0K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026